GW Pharmaceuticals PLC (GWPH) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) from a sell rating to a hold rating in a research note published on Wednesday morning.

GWPH has been the topic of a number of other reports. ValuEngine upgraded shares of GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Wednesday. TheStreet upgraded shares of GW Pharmaceuticals PLC from a d+ rating to a c- rating in a research note on Tuesday, March 14th. Cantor Fitzgerald reiterated a buy rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. Maxim Group reiterated a buy rating and set a $135.00 price objective on shares of GW Pharmaceuticals PLC in a research note on Thursday, May 25th. Finally, Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC from a hold rating to a sell rating in a research report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average price target of $144.50.

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 1.17% during midday trading on Wednesday, hitting $103.50. 123,877 shares of the stock traded hands. The company’s 50-day moving average is $103.62 and its 200-day moving average is $115.89. The company’s market cap is $2.62 billion. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative net margin of 1,021.38% and a negative return on equity of 22.81%. The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.07 million. During the same quarter last year, the company earned ($0.06) earnings per share. The company’s revenue was down 23.0% compared to the same quarter last year. Equities research analysts expect that GW Pharmaceuticals PLC will post ($5.34) EPS for the current fiscal year.

WARNING: This report was first posted by Mideast Time and is the property of of Mideast Time. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.mideasttime.com/gw-pharmaceuticals-plc-gwph-upgraded-to-hold-at-bidaskclub/1802566.html.

A number of hedge funds have recently modified their holdings of GWPH. Trexquant Investment LP purchased a new stake in shares of GW Pharmaceuticals PLC during the fourth quarter valued at $497,000. Allianz Asset Management AG purchased a new stake in shares of GW Pharmaceuticals PLC during the fourth quarter valued at $1,418,000. Envestnet Asset Management Inc. increased its stake in shares of GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 264 shares in the last quarter. Fred Alger Management Inc. increased its stake in shares of GW Pharmaceuticals PLC by 28.6% in the fourth quarter. Fred Alger Management Inc. now owns 4,500 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 1,000 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of GW Pharmaceuticals PLC by 3.4% in the fourth quarter. Franklin Resources Inc. now owns 438,470 shares of the biopharmaceutical company’s stock valued at $48,999,000 after buying an additional 14,300 shares in the last quarter. Hedge funds and other institutional investors own 75.65% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GWPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.